246 related articles for article (PubMed ID: 27621150)
1. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.
Denney WS; Sonnenberg GE; Carvajal-Gonzalez S; Tuthill T; Jackson VM
Br J Clin Pharmacol; 2017 Feb; 83(2):326-338. PubMed ID: 27621150
[TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers.
Lee MR; Farokhnia M; Cobbina E; Saravanakumar A; Li X; Battista JT; Farinelli LA; Akhlaghi F; Leggio L
Neuropharmacology; 2020 Jun; 170():107788. PubMed ID: 31557492
[TBL] [Abstract][Full Text] [Related]
3. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study.
Lee MR; Tapocik JD; Ghareeb M; Schwandt ML; Dias AA; Le AN; Cobbina E; Farinelli LA; Bouhlal S; Farokhnia M; Heilig M; Akhlaghi F; Leggio L
Mol Psychiatry; 2020 Feb; 25(2):461-475. PubMed ID: 29728704
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.
Kong J; Chuddy J; Stock IA; Loria PM; Straub SV; Vage C; Cameron KO; Bhattacharya SK; Lapham K; McClure KF; Zhang Y; Jackson VM
Br J Pharmacol; 2016 May; 173(9):1452-64. PubMed ID: 26784385
[TBL] [Abstract][Full Text] [Related]
5. Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.
Adusumalli S; Jamwal R; Obach RS; Ryder TF; Leggio L; Akhlaghi F
Drug Metab Dispos; 2019 Aug; 47(8):874-882. PubMed ID: 31182423
[TBL] [Abstract][Full Text] [Related]
6. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
7. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma.
Adusumalli S; Jamwal R; Leggio L; Akhlaghi F
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Nov; 1130-1131():121820. PubMed ID: 31670107
[TBL] [Abstract][Full Text] [Related]
10. Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies.
Farokhnia M; Portelli J; Lee MR; McDiarmid GR; Munjal V; Abshire KM; Battista JT; Browning BD; Deschaine SL; Akhlaghi F; Leggio L
Brain Res; 2020 Aug; 1740():146851. PubMed ID: 32339499
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457.
Sulima A; Akhlaghi F; Leggio L; Rice KC
Bioorg Med Chem; 2021 Nov; 50():116465. PubMed ID: 34662828
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H
Venail F; Attali P; Wersinger E; Gomeni R; Poli S; Schmerber S
Br J Clin Pharmacol; 2018 Dec; 84(12):2836-2848. PubMed ID: 30152527
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.
Badman MK; Chen J; Desai S; Vaidya S; Neelakantham S; Zhang J; Gan L; Danis K; Laffitte B; Klickstein LB
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):395-410. PubMed ID: 31823525
[TBL] [Abstract][Full Text] [Related]
14. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
15. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Nass R; Pezzoli SS; Oliveri MC; Patrie JT; Harrell FE; Clasey JL; Heymsfield SB; Bach MA; Vance ML; Thorner MO
Ann Intern Med; 2008 Nov; 149(9):601-11. PubMed ID: 18981485
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
17. A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers.
Cobbina E; Lee MR; Leggio L; Akhlaghi F
Clin Pharmacokinet; 2021 Apr; 60(4):471-484. PubMed ID: 33155163
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5-Subtype Selective GABA
Gurrell R; Whitlock M; Wei H; Shen Z; Ogden A
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):756-764. PubMed ID: 33465277
[TBL] [Abstract][Full Text] [Related]
19. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.
Campbell GA; Patrie JT; Gaylinn BD; Thorner MO; Bolton WK
Nephrol Dial Transplant; 2018 Mar; 33(3):523-530. PubMed ID: 28340044
[TBL] [Abstract][Full Text] [Related]
20. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers.
Garcia JM; Polvino WJ
Oncologist; 2007 May; 12(5):594-600. PubMed ID: 17522248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]